Sohonos (Palovarotene) Patent Expiration, LOE Window & CMS Spending

Sohonos (Palovarotene) by Ipsen Biopharmaceuticals: FDA Orange Book LOE 2037-08-16, 0 AB generics, $6.9M 2024 CMS Part D & Medicaid spend, and $47,880 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIpsen Biopharmaceuticals
FDA Application & PathwayN215559 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-08-16
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$6.9M
2024 Medicare Part D Spend$3.3M
2024 Medicaid Spend$3.6M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($47,880 intro WAC)